PBI Next Generation PCT System Presentation
at The American Society for Mass Spectrometry

Pressure BioSciences Unveils Barocycler 2320EXT at
ASMS Conference in Texas - News Report on Small Cap Nation

The introduction of the Barocycler 2320EXT, PBI's next generation PCT-based Instrument, took place during the recent annual conference of the American Society for Mass Spectrometry ("ASMS") in San Antonio, TX. The c ompelling advantages of the Pressure BioSciences' patented PCT Platform were prominently featured in multiple presentations at the same International conference. The Barocycler 2320EXT is expected to be the centerpiece of the recently announced co-marketing agreement with global life sciences analytical technology leader SCIEX

Six Separate Research Groups Present the PBI System
Scientists from six separate research groups made independent presentations on the Company's PCT-based product line at the same International conference. Results presented indicated that the Company's PCT-based instruments and consumables, when used in the preparation of samples for mass spectrometric analysis, resulted in critically enabling qualitative and quantitative improvements and/or improved time or cost efficiency. Presentations were made by scientists from the Children's Medical Research Institute (Sydney, Australia), the Johns Hopkins University School of Medicine, the Center for Food Safety and Applied Nutrition - Food and Drug Administration (FDA/CFSAN), Northwestern University, and Pressure BioSciences together with Protifi LLC.

Largest Annual Meeting of Mass Spectrometry Professionals
The ASMS conference is one of the largest annual meetings of mass spectrometry professionals worldwide. PBI took advantage of this opportunity to unveil the Barocycler 2320EXTREME. This newest addition to PBI's product line was designed with a number of new and enhanced features and benefits that should enable scientists better access to the biomolecules (e.g., proteins, lipids, nucleic acids) in samples being studied, with the potential to result in new biological insights and discoveries, and rapid growth for PBI.
About Pressure BioSciences, Inc. 
Pressure BioSciences, Inc. ("PBI") (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e. pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 275 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.      

PBI Pressure Cycling Technology - A Game Changer
Download the SWI Research Report Here
 S tockWatchIndex  and SWI Research (SWI) are not registered investment advisers and the information  provided herein or any other SWI publication is not to be construed as personal financial advice, or a solicitation to buy or sell stock. SWI makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in its publications or on its web sites. Some of the published information has been provided by the companies covered, generated by publicly available sources, or what SWI deems to be reliable third party entities, but SWI does not guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or  warrant any results from use of the information. Readers are encouraged to consult their personal financial adviser before making any decisions to buy, sell or hold any securities mentioned herein. StockWatchIndex is not responsible for any error, mistake or shortcoming that may be occasioned at the time of publishing of the information in this publication, any other SWI publication, or its web sites and is not obligated to update and/or correct information. No liability is accepted by StockWatchIndex whatsoever for any direct, indirect or consequential loss arising from the use of the information. SWI expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information provided. SWI has been engaged by Small Cap Nation, an on-demand video news and information broadcasting platform and will be compensated in cash for the publication of the information herein . The included information is subject to change without notice. Please visit  www.swiresearch.com/#!legal-ease/lmvw1   for a full text of our Disclaimer, Privacy policy and Terms of Use.